v3.26.3
Basis of preparation and statement of compliance - Significant investments in subsidiaries (Details)
€ in Thousands
6 Months Ended 12 Months Ended
Feb. 24, 2026
Jan. 14, 2026
Jun. 30, 2026
EUR (€)
entity
Jun. 30, 2025
Dec. 31, 2025
Basis of preparation and statement of compliance          
Number of entities being consolidated | entity     2    
Hepalys Pharma, Inc          
Basis of preparation and statement of compliance          
Proportion of ownership interest 13.68% 13.92% 13.68% 15.00% 14.64%
Inventiva Inc.          
Basis of preparation and statement of compliance          
Percent of ownership interest     100.00%    
Non-controlling interest | €     € 0